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Abstract 
This paper reviews features of numerous tools, techniques and technologies that help to identify and 
detect early risk of diabetes. The paper uses systematic literature review (SLR) guidelines and searched 
most of the popular journals limiting the results tied to studies that discussed the screening and 
detection of the risk of diabetes. We reviewed the architecture, features and limitations of the various 
tools and technologies using the following classification: Continuous Glucose Monitoring Systems 
(CGMS), Flash Glucose Monitoring Systems (FGMS) and the Unobtrusive Systems. Under the 
unobtrusive system, we studied the Child Health Improvement through Computer Automation 
(CHICA) system and while there are pieces of evidence that proves its benefits and usefulness, we 
found some required enhancements in areas of decision support system, data entry automation and 
flexible integration with other systems.  Future work will examine the usage of intelligent automation 
to detect early risk of diabetes during a patient-physician visit. 
Keywords automation, blood glucose monitoring, decision support system, diabetes mellitus, 
Electronic Management Records (EMR). 
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1 Introduction 
The statistics from the World Health Organization (2016) are staggering sowing a reported rise of 
diabetes globally. The number of people living with diabetes soar to 422 million in 2014 from 108 
million in 1980 representing an 8.5% increase. In 2012, 3.7 million people reportedly died before they 
reached the age of 70 years while 1.6 million people died in 2016 as a result of diabetes (WHO, 2016). 
In a subsequent report published by the International Diabetes Federation (IDF) (2019), based on the 
WHO (2016) data it is estimated that 463million people are currently diabetic with about 4.2 million 
deaths in 2019. A further projection showed 578.4 million and 700.2 million people will be suffering 
from diabetes in 2030 and 2045 respectively. These figures illustrate the stark reality that diabetes has 
become a major global health issue that needs to be managed and is also fast becoming a threat to 
human life.  
The objective of this study is to review the tools, techniques and technology that can help screen, 
identify, and detect the risk of diabetes at an early stage. We hope that this work will benefit the 
research communities in the area of automated screening, diagnosis and detection of diabetes while 
avoiding the expensive management of Diabetes. According to El-Gayar, Timsina, Nawar, and Eid 
(2013), diabetes is a chronic illness that requires constant continuous care, management, and support 
to prevent further complications. Dovc and Battelino (2020) describe diabetes as a condition caused 
by autoimmune destruction of the cells responsible for secreting insulin into the body causing an 
unbalanced glucose level with reliance and dependence on the infusion of insulin. This disease occurs 
if adequate insulin is not produced by the pancreas for regulating blood sugar or glucose (WHO, 2016). 
After diabetes is screened detected and diagnosed, the affected individual will then undergo a tough 
regime or series of tasks that include constant glucose monitoring, care, supports, management, and 
exercise. These are required to avoid hypoglycaemia (low blood sugar), hyperglycaemia (high blood 
sugar level) in the blood and lead a normal life. Unfortunately, these tasks must be self-managed by 
the individual and supervised by a healthcare professional. El-Gayar et al. (2013) defined Self-
management as a set of tasks that must be done by an individual to live well and deal with the 
associated chronic conditions or complications of an illness noting also that these tasks can have an 
associated mental and emotional and physical effect on an individual.  
Diabetes self-management process often comes with the following challenges. First, high cost of 
devices, proper treatment plans, changes in lifestyle, absence of resources for education and lack of 
adherence to treatment plans (Brown & Bussell, 2011; Buysman, Anderson, Bacchus, & Ingham, 2017) 
set a high barrier to constant monitoring and control of sugar level. Second, according to Bailey, 
Walsh, and Stone (2018), there are various factors to consider and more than one way to measure and 
achieve good glycaemic control. Finally, the self-management process requires a great deal of data 
acquisition, storage and analysis according to El-Gayar et al. (2013), which can be expensive and 
demand a high learning curve despite the advances in care and support monitoring tools and 
technology that helps with these processes.  
Early screening aid preventive care according to the guidelines set by WHO.  As acknowledged by the 
US Preventive Task Force (1996), preventive care in line with set standard guidelines is an important 
factor to prevent diseases and avoiding future complications among children. Preventive care also 
aligns with the American Diabetes Association (ADA) recommendation for detecting Type 1, 2 
Diabetes (T2D) through screening. Attaining preventive care through screening by medical institutions 
have a lot of barriers such as physician time constraints, lack of knowledge about screening, basic 
management for diabetes capacity, lack of education and poor communication with patients and 
families (Lee et al., 2014). Hannon et al. (2017) acknowledge that an unobtrusive automated system 
could help eliminate the barriers of screening for prediabetes and Type 2 Diabetes.  
This paper is a research-in-progress and the outcome will eventually assist in constructing an 
unobtrusive automated system for detecting diabetes. 
The review is organized in the following way: Section 2 talks about the methodology used in carrying 
out the literature review. Section 3 presents a detailed review of the tools and technologies of diabetes 
as a result of the literature analysis and synthesise. while section 4 concludes the paper and introduces 
future works.  
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2 Methodology 
The following steps were adopted in our strategy to search and analyse the relevant literature for 
reviewing the various tools and technologies.  
We used the SLR methods provided by Chomutare et al. (2011) who observed that the research-based 
literature provides adequate history, justification and applications of the tools, Additionally, the 
literature-based applications compare the functionality alongside the recommendations in clinical 
guidelines. 
2.1 Search Strategy 
The search was mainly conducted using Google Scholar, an online search platform and the School 
University Library portal. Using these portals, we were able to access works from popular journals 
such as Medline, ScienceDirect, ACM (Association for Computing Machinery) Digital Library, IEEE 
(Institute of Electrical and Electronics Engineers), Scopus, PubMed and School University library. The 
following combinations of words and phrases such as “automation”, diabetes” “self-management” and 
“glucose sensors” were used to search while limiting the results to articles that were published from 
2016 to date. The search was initially based on the metadata of the paper such as title, abstract, and 
keywords. Further reviews were conducted on the full-body text to extract journals that were relevant 
to the early screening and detection of diabetes using automation or computer applications.  
2.2 Selection Criteria 
Using the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) flow 
diagram (depicted in Figure 1) as proposed by McInnes et al. (2018), we were able to depict and show 
the selection flow through the different phases of the systematic review. 
Due to the rapid changes in technology in this domain, our scope of the search was restricted to 
articles published during the last 4 years (2016–2020). This allowed us to reduce our search results to 
2380. The large number of publications were because the search returned widespread results and 
included articles that covered a wide range of topics from management, administration to psychology 
of diabetes treatment.  
The second phase was the manual review of the titles and abstract. This review aimed to restrict the 
results to articles that directly talks about the technologies for early screening and detection of 
diabetes. This inclusion criterion allowed us to narrow the results to 475 papers that had a clear focus 
on diabetes method for early screening and detection. 
Papers which were focused on the discussion of Machine Learning and artificial intelligence 
procedures were further excluded because the objective of our research was aimed at automation, 
decision support system, tools and technologies that help the detection of diabetes. To finally select 
relevant literature, we narrowed our results to diabetes detection and screening tools filtering out 
research papers that are not written in the English language bringing the search results to 70. We were 
able to include an additional 10 articles from the review of references from some of the selected 
published work.  
 
 
Figure 1: Literature Review Selection Process 
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3 Literature Review 
In line with our objective early detection of the risk of diabetes, we begin by summarizing the list of 
requirements that must be satisfied by the tools and technologies under review. The requirements 
include self-monitoring (by capturing weight, insulin levels, blood pressure), alerts and reminders, 
integration with a Personal Health Record system (PHR), communication and a decision support 
system for screening for diabetes. As suggested by Huang, Soljak, Boehm, and Car (2018) there are 
numerous diabetes applications, tools technology available both commercially and understudy which 
meets these requirements. 
Next, we proceed to classify and discuss the various tools and technologies. Ghosh, Bhattacharjee, and 
Nasipuri (2020) classified blood glucose estimation and measurement as direct and indirect based on 
the level of involvement and participation of the patient. They defined the direct method as 
technologies that enable the determination of diabetes by taking blood samples with the awareness of 
the patient and indirect as a non-invasive method of screening for diabetes when the patient is 
unaware. This non-invasive nature was also implicitly referred to as unobtrusive in Anand, Biondich, 
Liu, Rosenman, and Downs (2004)’s study.  However, for ease of review, we have classified the 
technologies that can help detect, and screen for the risk of diabetes as follows: Continuous Glucose 
Monitoring Systems (CGMS), Flash Glucose Monitoring System (FGM) and Unobtrusive Systems.  The 
CGMS and FGMS are classified as direct method while Unobtrusive is indirect. 
 
3.1 Direct Method Systems 
3.1.1 Continuous Glucose Monitoring Systems (CGMS) 
A popular method for screening and early detection of diabetes is glucose monitoring. Glucose 
monitoring helps individuals to assess their glycaemic status and know their insulin requirements. 
Historically, glucose concentration was decided and assessed by using placing a piece of copper in the 
urine (Dovc & Battelino, 2020). These evolved into the Self-Monitoring of Blood Glucose (SMBG). 
SMBG works by detecting the glucose level from the blood through finger pricking. SMBG is 
considered inconvenient and unacceptable by diabetic patients (Lucisano, Routh, Lin, & Gough, 2016) 
evolving to a more portable handheld meter called the Continuous glucose monitoring (CGM) device 
which can be used to measure glucose level directly from the blood. CGM systems have been available 
for 15 years (International Standard Organisation, 2003).  
The CGM systems consist of disposable sensors that are used for measuring the level of glucose in 
interstitial fluid (Dovc & Battelino, 2020; Fokkert et al., 2017) at intervals and can send the semi-
continuous glucose (Fokkert et al., 2017) data to a dedicated receiver or smartphone or cloud systems 
for further processing, analysis and decision. The shared data provides information on glucose levels 
fluctuations and variability. The CGM can exist in an implantable where the form sensor is implanted 
in the skin by health care professionals and data can be sent to a body device (Dovc & Battelino, 2020).  
Various studies highlight the usefulness of CGMS and improved glycaemic control because of its use 
(Langendam et al., 2012; Poolsup, Suksomboon, & Kyaw, 2013). Research has also shown the efficacy 
of CGM in reducing HBA1c and avoiding hypoglycaemia (Juvenile Research Group, 2008). Dovc and 
Battelino (2020) note that the CGMS have been successfully used in pregnancy complicated by Type 1 
Diabetes(T1D) leading to savings worth millions of US dollars. CGM, as endorsed by the American 
Diabetes Association (2019) have also been used as a standard of care for people with T1D. 
Besides the high prediction accuracy (Bailey et al., 2018) of the CGM devices, there are other 
important features of the CGM such as the ease of use, miniaturization, data management and a secure 
connection with different applications and data.  The capability to connect to other devices is an 
important feature that allows the device to provide add-on features such as decision support, 
notification and reminders to the individuals and healthcare professionals. Dovc and Battelino (2020) 
compared a few of CGM products such as G6, Guardian Sensor 3, Eversense and Freestyle libre/libre 2 
manufactured by Dexcom, Medtronics, Senseonics and Abbott respectively. Out of the 4 devices, only 
Eversense is implanted while the others are inserted.  
In addition, the G6, Guardian Sensor 6 and Eversense have claims, trends or alerts with some data 
sharing capabilities (Bailey et al., 2018; Dovc & Battelino, 2020). The data-sharing features allow 
vendors to develop apps that can extend the features of the CGM devices. Bailey et al. (2018) list 
mobile phone apps and software that integrates with CGM to provide and display glucose data. 
Dexcom has G5mobile phone, Medtronic has a Guardian connect app, Abbot has libre link and libre 
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linkup software. Bailey et al. (2018) further note that these mobile apps allow for the data sharing, 
connectivity and provide other experience that allows the increase in the safety of Seniors who are 
either incapable of self-management or support. 
However, the device comes with its limitations. CGMS require frequent calibration of the system, 
about twice daily to allow for a reliable “correlation” (Fokkert et al., 2017) between interstitial and 
capillary glucose results. Secher, Ringholm, Andersen, Damm, and Mathiesen (2013) and Murphy et 
al. (2008) argued that there are limited benefits and mixed outcomes for the application on pregnant 
women with diabetes and they provided a list of barriers that includes skin limitations, frequent alarm 
notifications, cost and inconsistencies between sensor values. Feig et al. (2017), in his study documents 
about 80% expressing frustrations with 48% experiencing skin irritations. Most of these devices have 
been less intuitive and not particularly user friendly and will require the help of professionals to set up 
and use. Deriving the maximum benefits of the CGM and CGM Extensions is largely dependent on 
appropriate usage. The integration with an Electronic Medical Record (EMR) or Personal Health 
System (PHR) system or the sharing of data with a qualified healthcare professional is vital. Some of 
the CGM devices reviewed by Bailey et al. did not show any visible integration with these systems. The 
chance of preventing diabetes is significantly reduced if the data is not thoroughly analysed by a 
healthcare professional.  
3.1.2 Flash Glucose Monitoring (FGM) 
The frequent calibration of the CGM among other limitations were the reasons for the introduction of 
the Flash Glucose Monitoring (FGM) System. Abbott introduced the Freestyle Libre, a Flash Glucose 
Monitoring system into the market in 2014 (Heinemann & Freckmann, 2015) and as the time of this 
study, they were the only manufacturer of the system. According to Fokkert et al. (2017), FGM systems 
are compact and lightweight and do not require frequent calibration by CGMs only a factory 
calibration. Heinemann and Freckmann (2015) further confirm that frequency of calibration is a major 
difference between the FGM and CGM is calibration. FGM systems also measure interstitial glucose 
using disposable electronics and subcutaneous sensor attached to the skin using a button look-alike to 
hold it firmly in position. This can measure glucose every minute for 14 days. The sensor is then 
scanned, and data displayed on a screen to show trends.  
The FGM systems are a vital substitute for individuals who do not want the painful finger pricking 
associated with Self-Monitoring Glucose System (SMBG) or who do not want to be bothered with the 
frequent alarm notification and calibrations from CGMs. Scott, Bilous, and Kautzky-Willer (2018) 
report the high accuracy of the device and that it was not affected by parameters such as type of 
diabetes, pregnancy sage, age or BMI and the system is easy to use and can provide up to 14 days 
glucose data. According to, Heinemann and Freckmann (2015), the FGM devices surpasses the 
Conventional blood group self-monitoring in the following ways.  
• “Intermittent capillary sampling only provides a snapshot of glucose concentrations” 
(Heinemann & Freckmann, 2015).  
• Accuracy, according to international standards (Fokkert et al., 2017) is +/- 15% for glucose 
level greater than or equal to 100mg/dl and +/- 15 mg/dl for glucose level less than 100mg/dl.  
• Scott et al. (2018) described the accuracy of the Freestyle Libre System as a combination to the 
robustness of patient characteristics such as age, BMI, insulin usage, pregnancy stage and type 
of diabetes.  
• BG self-monitoring might take a few minutes while the FGM can scan and read results within 
seconds. This information according to their study is enough to recommend its usage in 
pregnant women to support and optimize their glycaemic control. 
• Conventional BG monitoring is more expensive than FGM at an average rate of 5-8 tests per 
day. 
Despite its benefits and applications for detecting the glucose status of individuals, the FGMS has 
some limitations. In a study carried out by Scott et al. (2018), although there was a favourable rating in 
user experience, they found out that 7% of the participants reported associated symptoms such as 
bleeding, bruising, erythema, itching, and pain while Fokkert et al. (2017) reports limitations such as 
physiological lag time, sensitivity to local fluctuations. Comprehensive Education is also essential and 
plays a huge role in the adoption (Al Hayek, Robert, & Al Dawish, 2017; Bruttomesso et al., 2019). 
Adolfsson, Parkin, Thomas, and Krinelke (2018) sees the less frequent factory calibration as a 
limitation as patients are unable to recalibrate when glucose values do not match confirmed blood 
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glucose test results. They also argued that the 8-hour monitoring trend might make the system easy to 
use but offers a potentially dangerous limitation to patients at risk of hypoglycaemia. 
3.2 Unobtrusive Systems 
There are few justifications for the need for unobtrusive systems. Firstly, limitations such as frequent 
calibration, alarm notifications, costs, sensor value inconsistencies, skin irritation, intensive education 
associated with invasive systems and direct systems like Glucose monitoring systems have made them 
very popular. Secondly, the increasing need for further analysis by a healthcare professional and 
integration with an EMR system. Lastly, the rising importance and popularity of preventive health care 
where healthcare providers place a priority on understanding the risk profile of patients to eliminate 
future interventions. An ideal glucose monitoring system would be unobtrusive, “not attached to the 
skin, retain stable long-term calibration, and require minimal maintenance, if any, by the user” 
(Lucisano et al., 2016, p. 1). 
According to the US Preventive Services Task Force, unnecessary interventions can be prevented by 
early analysis and screening for diabetes based on established guidelines and using technological tools 
that can be used by patients and comply with set guidelines (Carroll et al., 2011). The guidelines talk 
about the Just-in-time information delivery and defined it as screening and receiving notifications 
during the patient-physician visits while the physician is taking notes (Carroll et al., 2011). Although 
Preventive systems are increasingly becoming popular and ubiquitous, we shall limit the scope of 
discussions to the Child Health Improvement through Computer Automation (CHICA) system which is 
considered a CHICA system. 
3.2.1 Overview of CHICA System 
Anand et al. (2004) described the CHICA system as a client-server architecture system while Hannon 
et al. (2017) explains that the system is tightly integrated with an electronic medical record and uses a 
pre-screener form for eliciting information from patients. The pre-screener form can be accessed on 
basic mobile devices (Hannon et al., 2017) and captures information on family history, race, ethnicity, 
and an assessment form for physicians. The forms are subsequently scanned using Optical Character 
(OCR). 
It contains a module that applies pre-defined logic using Ardern MLM Rule-based parsing processor to 
analyse captured data and decision support while ensuring compliance with the general standard 
practice in a paediatric clinic (Carroll et al., 2013; Carroll et al., 2011). A tightly coupled integration 
with an Electronic Medical Record (EMR) provides the setups and configuration of diagnostic codes, 
orders, prescriptions and laboratory data from an integrated and centralized portal (Biondich & 
Grannis, 2004). Integration with other systems provides the CHICA system with a feature extension 
that allows the sending of information to the laboratory for testing, send out a notification for follow 
up appointments and generates reminder phone calls for an appointment. It also makes the referral 
and follow-up calls based on glucose levels. 
The CHICA system has many applications and benefits. Hannon et al. (2017) study showed that the 
application of CHICA automation increased the rates of screening of diabetes 4 times among youths 
with a BMI above 85th percentile and 2 or more risk factors according to the recommended ADA 
guidelines. The increase in follow-up attendance can also be attributed to the system.  
However, the tight integration of the system with the Indiana University Health primary health care 
portal and application serves as a major limitation for the CHICA system. Although as quickly noted by 
Hannon et al. (2017), there is ongoing work to redevelop CHICA as a web service to provide more 
availability and widespread usage. 
4 Conclusion 
In this paper, we classified the different ways of detecting and screening for glucose into a continuous 
glucose monitoring system, flash glucose monitoring system and the unobtrusive system. For each of 
the category, we discussed the architectural differences, strengths, and limitations. Both FGM and 
CGM have been shown to share limitations such as skin irritations, frequent alarm notifications, cost 
and inconsistencies between sensor values and difficulty in learning to use the devices. These 
limitations with FGMs and CGMs devices have made the Unobtrusive systems very popular. Our study 
is limited to the CHICA system for the unobtrusive system. The main benefits of the Unobtrusive 
system are the capability to assist in detecting and early prevention of diabetes thereby potentially 
avoiding the hassles of self-management\care of diabetes and making required lifestyle changes.  
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The CHICA system also comes with limitations such as tight integration with the institutions EMR and 
the manual method of completion of forms by patients and physicians. Our studies show that there 
could be improvements in areas such as data entry automation, decision support system and flexibility 
to integrate and work with the various hospital systems. We believe that recent technological advances 
such as the highly fast-paced and scalable robotics process automation, artificial intelligence, and 
machine learning in the combined areas of automation and decision support can greatly improve the 
outcomes of the unobtrusive system. Future work will examine how to improve these areas for the 
screening of the risk of diabetes during patient-physician visits. 
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